Mar 17th, 2019

Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial

Michel Azizi, Roland E. Schmieder, Felix Mahfoud, Michael A. Weber, Joost Daemen, Melvin D. Lobo, Andrew S.P. Sharp, Michael J. Bloch, Jan Basile, Yale Wang, Manish Saxena, Philipp Lurz, Florian Rader, Jeremy Sayer, Naomi D.L. Fisher, David Fouassier, Neil C. Barman, Helen Reeve-Stoffer, Candace McClure, Ajay J. Kirtane, and on behalf of the RADIANCE-HTN Investigators

Originally published 17 Mar 2019 | Circulation

ReCor Medical

Background:

The multicenter, international, randomized, blinded, sham-controlled RADIANCE-HTN SOLO trial (A Study of the ReCor Medical Paradise System in Clinical Hypertension) demonstrated a 6.3 mm Hg greater reduction in daytime ambulatory systolic blood pressure (BP) at 2 months by endovascular ultrasound renal denervation (RDN) compared with a sham procedure among patients not treated with antihypertensive medications. We report 6-month results after the addition of a recommended standardized stepped-care antihypertensive treatment to the randomized endovascular procedure under continued blinding to initial treatment.

The full article can be found at https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.040451.